Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Advagen Pharma Ltd., priced at $0.7080 per EA under NDC 72888011830. Its NADAC has been published 134 times since Jan 31, 2024.
FDA first approved this application on Apr 6, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
Advagen Pharma Ltd.NDC
72888011830
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216682FDA Approved
4/6/2023
TE Code
AB
On Market Since
4/6/2023
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 134 times since Jan 31, 2024, and over the history we have for it it has declined 39.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7080 per EA |
|---|---|
| All-time high | $1.1664 (Feb 14, 2024) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7172 |
| 52-week low | $0.6572 |
| Median price | $0.7135 |
| Average price | $0.7715 |
| Largest weekly change | -27.7% (Nov 20, 2024) |
| Weeks tracked | 134 |
| Tracking since | Jan 31, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Advagen Pharma Ltd., is $0.7080 per EA (NDC 72888011830), effective Aug 19, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 39.3%. It has been tracked across 134 weekly CMS publications since Jan 31, 2024.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since Jan 31, 2024, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $1.1664 (Feb 14, 2024), with a median of $0.7135 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEVIMELINE HCL 30 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 72888011830) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.